medwireNews: Results of the PROLOGUE study show that the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin has no greater effect than other antidiabetic medications on progression of carotid intima-media thickness (cIMT).
But the researchers stress that although sitagliptin did not slow cIMT progression relative to control antidiabetic treatment, this does not mean it is not effective against atherosclerosis, given that some of the drugs used in the control group, such as pioglitazone, reportedly have anti-atherosclerotic properties.
Only DPP-4 inhibitors, glucagon-like peptide-1 analogues and insulin were barred in the control group. During 2 years of follow-up, average cIMT increased by 0.002 mm in these 220 patients and decreased by 0.002 mm in the 222 patients taking sitagliptin.
Measurement of cIMT was blinded and conducted in a central laboratory, avoiding bias and ensuring consistency, researcher Jun-ichi Oyama (Saga University, Japan) and colleagues note in PLoS Medicine.
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016